MIF-dependent control of tumor immunity
JT Noe, RA Mitchell - Frontiers in immunology, 2020 - frontiersin.org
Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage
migration inhibitory factor (MIF) has since been found to be expressed by nearly every …
migration inhibitory factor (MIF) has since been found to be expressed by nearly every …
Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities
C O'Reilly, M Doroudian, L Mawhinney… - Medicinal research …, 2016 - Wiley Online Library
Strong evidence has been presented linking chronic inflammation to the onset and
pathogenesis of cancer. The multifunctional pro‐inflammatory protein macrophage migration …
pathogenesis of cancer. The multifunctional pro‐inflammatory protein macrophage migration …
Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression
Rationale: Regression of atherosclerosis is an important clinical goal; however, the
pathways that mediate the resolution of atherosclerotic inflammation and reversal of plaques …
pathways that mediate the resolution of atherosclerotic inflammation and reversal of plaques …
[HTML][HTML] Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration
Extra-cranial malignant rhabdoid tumors (MRTs) and cranial atypical teratoid RTs (ATRTs)
are heterogeneous pediatric cancers driven primarily by SMARCB1 loss. To understand the …
are heterogeneous pediatric cancers driven primarily by SMARCB1 loss. To understand the …
BCL6-dependent TCF-1+ progenitor cells maintain effector and helper CD4+ T cell responses to persistent antigen
Soon after activation, CD4+ T cells are segregated into BCL6+ follicular helper (Tfh) and
BCL6–effector (Teff) T cells. Here, we explored how these subsets are maintained during …
BCL6–effector (Teff) T cells. Here, we explored how these subsets are maintained during …
[HTML][HTML] A multi-targeted approach to suppress tumor-promoting inflammation
Cancers harbor significant genetic heterogeneity and patterns of relapse following many
therapies are due to evolved resistance to treatment. While efforts have been made to …
therapies are due to evolved resistance to treatment. While efforts have been made to …
The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component
Classical Hodgkin lymphoma (cHL) is characterized by a minority of tumor cells derived from
germinal center B-cells and a vast majority of non-malignant reactive cells. The tumor cells …
germinal center B-cells and a vast majority of non-malignant reactive cells. The tumor cells …
Hallmarks of cancer affected by the MIF cytokine family
R Mora Barthelmess, B Stijlemans… - Cancers, 2023 - mdpi.com
Simple Summary The aim of this review is to summarize the available information regarding
the MIF family in cancer, comprising MIF and DDT. Both cytokines are highly expressed in …
the MIF family in cancer, comprising MIF and DDT. Both cytokines are highly expressed in …
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
RA de Azevedo, E Shoshan, S Whang, G Markel… - …, 2020 - Taylor & Francis
Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients
with metastatic melanoma, yet, durable complete response; even with …
with metastatic melanoma, yet, durable complete response; even with …
[HTML][HTML] Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach
K Mangano, E Mazzon, MS Basile, R Di Marco… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Abstract Macrophage Migration Inhibitory Factor (MIF) is a pro-inflammatory cytokine
expressed by a variety of cell types. Although MIF has been primarily studied for its role in …
expressed by a variety of cell types. Although MIF has been primarily studied for its role in …